- Home
- OABI vs GNLX Comparison
OABI vs GNLX Comparison
Compare OABI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OABI | GNLX |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.0M | 202.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | OABI | GNLX |
|---|---|---|
| Price | $1.95 | $4.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.67 | ★ $19.75 |
| AVG Volume (30 Days) | ★ 547.4K | 302.2K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,094,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $66.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $1.22 | $1.99 |
| 52 Week High | $4.17 | $8.54 |
Technical Indicators
Market Signals| Indicator | OABI | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 66.48 | 38.59 |
| Support Level | $1.69 | $4.41 |
| Resistance Level | $1.64 | $5.89 |
| Average True Range (ATR) | 0.12 | 0.51 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 98.18 | 18.24 |
Price Performance
Historical ComparisonAbout OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.